Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


News Briefs: Lung Screening Recs; Stryker Purchase; CMS News

This article was originally published in The Gray Sheet

Executive Summary

Federal task force issued final recommendations advising CT screening for people at high risk for lung cancer. Stryker acquired Patient Safety Technologies. CMS announced updates on accountable care organizations. More news briefs.

You may also be interested in...

CT Lung Cancer Screening Is Up For National Medicare Coverage Consideration

CMS agency accepted two formal requests to open a national coverage analysis for low-dose computed tomography as a lung-cancer screening tool for high-risk, but asymptomatic individuals, and plans to hold a MedCAC meeting on the topic in April.

BRCA Reimbursement Cut Heightens Tensions Between CMS And Lab Industry

CMS has extended the comment period on its nearly 50 percent BRCA testing reimbursement cut to the end of February. But comments from lab and diagnostics groups so far try to underscore the “capriciousness and lack of transparency” that CMS displayed when it made the cut. Experts say the agency is unlikely to change its mind.

Reimbursement Briefs: CMS Delivery Reform Results; Hospital Differences Assessed; PCORI Updates

CMS releases results for health care delivery system reform initiatives. Health Affairs study explores differences between high- and low-price hospitals. PCORI adds more high-impact topics to pragmatic studies initiative and approves $5 million to fund methods research.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts